Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Inventory (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Inventory for 14 consecutive years, with $467000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Inventory fell 33.29% to $467000.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $467000.0, a 33.29% decrease, with the full-year FY2023 number at $501000.0, down 85.42% from a year prior.
  • Inventory was $467000.0 for Q2 2025 at NovaBay Pharmaceuticals, down from $473000.0 in the prior quarter.
  • In the past five years, Inventory ranged from a high of $4.1 million in Q3 2022 to a low of $467000.0 in Q2 2025.
  • A 5-year average of $2.1 million and a median of $2.1 million in 2021 define the central range for Inventory.
  • Peak YoY movement for Inventory: surged 457.33% in 2022, then plummeted 86.46% in 2024.
  • NovaBay Pharmaceuticals' Inventory stood at $3.2 million in 2021, then increased by 6.74% to $3.4 million in 2022, then tumbled by 85.42% to $501000.0 in 2023, then decreased by 5.59% to $473000.0 in 2024, then decreased by 1.27% to $467000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Inventory are $467000.0 (Q2 2025), $473000.0 (Q3 2024), and $700000.0 (Q2 2024).